Deaths from gastrointestinal bleeding have increased, but fatal bleeding risk per anticoagulated patient has declined despite ...

CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced it has entered into a definitive asset purchase ...

News and commentary from the world of gastroenterology and hepatology ...

Denmark: New research has revealed that among patients with chronic obstructive pulmonary disease and atrial arrhythmias such ...

The PAUSE-URO study evaluated the safety of a new protocol for patients using direct oral anticoagulants (DOACs) prior to elective urologic surgery.

Thrombolytic use in select stroke patients with recent direct oral anticoagulant (DOAC) ingestion did not raise the risk of the most feared bleeding complication, according to the largest-yet ...

Despite concerns about the potential bleeding risk, IV thrombolysis could be safely given to ischemic stroke patients within a day of direct oral anticoagulant (DOAC) therapy, according to ...

In patients with atrial fibrillation with low thrombosis risk but high bleeding risk, both standard- and low-dose DOACs are equally effective and safe. Standard-dose direct oral anticoagulant therapy ...

Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions HealthDay News — Early adoption of the direct oral anticoagulant (DOAC) ...

The prevalence of inappropriate direct oral anticoagulant (DOAC) dosing in patients with atrial fibrillation (AF) was 25%. Several demographic factors such as advanced age, presence of chronic kidney ...

CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced ...